Department of Paediatrics, Dr von Hauner Children's Hospital, LMU Munich, Munich, Germany.
Department of Paediatrics, Dr von Hauner Children's Hospital, LMU Munich, Munich, Germany; Department of Paediatrics, Comenius University Medical School, Bratislava, Slovakia.
Clin Nutr. 2020 Dec;39(12):3786-3796. doi: 10.1016/j.clnu.2020.04.012. Epub 2020 Apr 22.
Exclusive enteral nutrition induces remission, improves bone health and growth in paediatric Crohn's disease (CD) patients, but is highly demanding for patients. We investigated efficacy of partial enteral nutrition (PEN) on bone health, growth and course in CD patients and assessed microbial and metabolic changes induced by PEN.
We performed a two centre, non-randomized controlled intervention study in quiescent CD patients aged <19 years. Patients in intervention group received a liquid formula providing ~25% of daily energy for one year. At baseline, after 3, 6, 9 and 12 months, we collected data on bone, muscle (peripheral quantitative computertomography), anthropometry, disease activity (weighted paediatric CD activity index), metabolomic profile (liquid chromatography mass spectrometry), and faecal microbiome (16S rRNA gene sequencing).
Of 41 CD patients, 22 received the intervention (PEN) (mean age 15.0 ± 1.9 years, 50% male), 19 served as controls (non-PEN) (12.8 ± 3.1 years, 58% male). At baseline, mean bone quality was comparable to reference population with no improvement during the intervention. Relapse rate was low (8/41, PEN 4/22 and non-PEN 4/19, ns). PEN was not associated with microbiota community changes (beta diversity) but significantly reduced species diversity. Metabolome changes with upregulation of phosphatidylcholines in PEN patients are likely related to lipid and fatty acid composition of the formula. PEN significantly improved growth in a subgroup with Tanner stage 1-3.
In our cohort of paediatric CD patients, PEN did not affect bone health but improved growth in patients with a potential to grow.
肠外营养可诱导儿科克罗恩病(CD)患者缓解,改善骨健康和生长,但对患者要求较高。我们研究了部分肠内营养(PEN)对 CD 患者骨健康、生长和病程的疗效,并评估了 PEN 诱导的微生物和代谢变化。
我们在处于缓解期的<19 岁 CD 患者中开展了一项两中心、非随机对照干预研究。干预组患者接受一种液体配方,在一年内提供约 25%的日常能量。在基线、3、6、9 和 12 个月时,我们收集了骨、肌肉(外周定量计算机断层扫描)、人体测量学、疾病活动(加权儿科 CD 活动指数)、代谢组学特征(液相色谱-质谱联用)和粪便微生物组(16S rRNA 基因测序)的数据。
41 例 CD 患者中,22 例接受了干预(PEN)(平均年龄 15.0±1.9 岁,50%为男性),19 例作为对照(非 PEN)(12.8±3.1 岁,58%为男性)。基线时,骨质量与参考人群相当,干预期间无改善。复发率较低(8/41,PEN 4/22 和非 PEN 4/19,无统计学差异)。PEN 与微生物群落变化(β多样性)无关,但显著降低了物种多样性。PEN 患者的代谢组学变化表现为磷脂酰胆碱上调,可能与配方中的脂质和脂肪酸组成有关。PEN 显著改善了 Tanner 分期 1-3 的患者的生长。
在我们儿科 CD 患者的队列中,PEN 并未影响骨健康,但改善了有生长潜力的患者的生长。